Ignite Creation Date:
2024-05-05 @ 7:19 PM
Last Modification Date:
2024-10-26 @ 9:46 AM
Study NCT ID:
NCT00642811
Status:
COMPLETED
Last Update Posted:
2011-10-04
First Post:
2008-03-19
Brief Title:
A Study of the Antiplatelet Effects Comparing Ticagrelor Ticag - AZD6140 With Clopidogrel Clop Responder and Non-responders
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Randomised Double-Blind Outpatient Crossover Study of the Anti-platelet Effects of Ticagrelor Compared With Clopidogrel in Patients With Stable Coronary Artery Disease Previously Identified as Clopidogrel Non-responders or Responders RESPOND
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RESPOND
Brief Summary:
The purpose of this study is to see how Ticagrelor a new oral reversible anti-platelet medication affects platelets Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets Blood clots prevent us from bleeding but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke This study investigated the effect of Ticagrelor on inhibition of platelet aggregation compared with clopidogrel in patients previously identified as non-responsive to clopidogrel
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None